



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dale J. Kempf, et al.  
Serial No: 10/802,829  
Filed: August 3, 2004  
Title: Method for Treating a Disease, Disorder or Adverse Effect Caused by an Elevated Serum Concentration of an UGT1A1 Substrate  
Confirmation No: 4276  
Group Art Unit: 1614  
Examiner: Raymond J. Henley III  
Attorney Ref: 7050USO2

February 27, 2007

03/01/2007 MBLAND 00000005 010025 10002029  
02 FC:1006 100.00 DA

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir/Madam:

To comply with 37 C.F.R. §1.97 and §198, Applicants submit the enclosed supplemental Form PTO-1449 and copies of all documents listed on that form with the exception of cited U.S. patents and U.S. patent application publications.

In accordance with MPEP §609 and §707.05(b), Applicants respectfully request that each document listed be given thorough consideration and that the Examiner cite each document of record in the prosecution history of this application by initialing Form PTO-1449 next to each document. Applicants request such initialing even if the Examiner does not consider a listed document to be sufficiently pertinent to use in a rejection or to be prior art for any reason. Applicants make this request so that each document becomes cited on the face of a patent issuing from this application.

Applicants submit this Supplemental Information Disclosure Statement in compliance with the duty to disclose information material to patentability under 37 C.F.R. §1.65, but by listing such documents Applicants are not admitting that such documents are necessarily relevant or prior art. Applicants intend no representation that the listed documents represent the results of a complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 C.F.R. §1.1049a0 and §1.106(b) and, in the course of such search, will review for relevance every document listed on the enclosed Form PTO-1449 even if not initialed.

\*\*\*\*\*

This Supplemental Information Disclosure Statement is filed together with a Request for Continued Examination and Amendment B. Applicants authorize the Commissioner to charge \$970 (\$180 for the Supplemental Information Disclosure Statement and \$790 for the Request for Continued Examination) to Deposit Account No. **01-0025**. Applicants believe that they do not owe any other fee(s) for this filing. If, however, Applicants do owe such fee(s), the Commissioner is hereby authorized to charge those fee(s) to Deposit Account No. **01-0025**. In addition, if there is ever any fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **01-0025**.

Respectfully submitted,  
Kempf et al.




Lydia N. Nenow, PTO Reg. No. 52,530  
Abbott Laboratories  
Dept. 0377, Bldg. AP6A-1  
100 Abbott Park Road  
Abbott Park, IL 60064  
(847) 938-0389 (tel)  
(847) 938-2623 (fax)

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service (Express Mail Label No. **EV 959284222 US**) on **February 27, 2007** with sufficient postage as first class mail (including Express Mail per MPEP §512), and addressed to **Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450**.



Lydia N. Nenow, PTO Reg. No. 52,530



Form PTO-1449

**PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 1 of 1

ATTORNEY DOCKET NO.

SERIAL NO.

7050USO2

10/802,829

APPLICANT

Dale J. Kempf et al.

FILING DATE

GROUP

August 3, 2004

1614

**U.S. PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
A1		US2004/0192624A1 (including 06/01/04 office action)	09/30/04	Kempf et al.	514/43	03/24/03

**FOREIGN PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes No

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)**

Ref. Desig.	Examiner's Initials	
C1		A. Radomska-Pandya et al., <i>Structural and Functional Studies of UDP-Glucuronosyltransferases</i> , DRUG METABOLISM REVIEWS 31(4):817-99 (1999)
C2		R.H. Tukey et al., <i>Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease</i> , ANN. REV. PHARMACOL. TOXICOL. 40:581-616 (2000)

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.